Cancer Vaccine Stops Melanoma Return in 1,137 Patients

A personalized mRNA cancer vaccine prevented deadly skin cancer from returning in over a thousand patients, marking the first successful Phase 3 trial for custom cancer treatment.

The breakthrough could reach patients as soon as next year.